83 related articles for article (PubMed ID: 20356529)
1. [Expression of nuclear autoantigenic sperm protein in platinum resistance ovarian cancer cell clones].
Wang HX; Tan Y
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(1):61-3. PubMed ID: 20356529
[TBL] [Abstract][Full Text] [Related]
2. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
3. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
[TBL] [Abstract][Full Text] [Related]
4. Quantitative differences in protein expression between cisplatin sensitive C0C1 ovarian carcinoma cells and cisplatin resistant C0C1/DDP cells.
Wang HX; Sun W; Li HL; Zhang WY
Chin Med J (Engl); 2009 Apr; 122(7):865-9. PubMed ID: 19493403
[No Abstract] [Full Text] [Related]
5. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
[TBL] [Abstract][Full Text] [Related]
6. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.
Le Moguen K; Lincet H; Marcelo P; Lemoisson E; Heutte N; Duval M; Poulain L; Vinh J; Gauduchon P; Baudin B
Proteomics; 2007 Nov; 7(22):4090-101. PubMed ID: 17994630
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines.
Dai Z; Yin J; He H; Li W; Hou C; Qian X; Mao N; Pan L
Proteomics; 2010 Nov; 10(21):3789-99. PubMed ID: 20957754
[TBL] [Abstract][Full Text] [Related]
8. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
9. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
Okuda T; Lin X; Trang J; Howell SB
Mol Pharmacol; 2005 Jun; 67(6):1852-60. PubMed ID: 15758147
[TBL] [Abstract][Full Text] [Related]
10. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
11. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
12. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
[TBL] [Abstract][Full Text] [Related]
13. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
[TBL] [Abstract][Full Text] [Related]
14. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
15. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
16. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis.
Alfonso P; Núñez A; Madoz-Gurpide J; Lombardia L; Sánchez L; Casal JI
Proteomics; 2005 Jul; 5(10):2602-11. PubMed ID: 15924290
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line.
Li SL; Ye F; Cai WJ; Hu HD; Hu P; Ren H; Zhu FF; Zhang DZ
J Cell Biochem; 2010 Mar; 109(4):625-33. PubMed ID: 20082317
[TBL] [Abstract][Full Text] [Related]
20. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
